Inherited retinal dystrophies (IRD) are a highly heterogeneous group of diseases characterized by the degeneration of photoreceptors and retinal pigment epithelium (RPE) cells. They affect approximately 1 in 3,000 people, and represent the major cause of incurable familial blindness, with more than 2 million people affected worldwide[@b1]. In general, IRD are classified according to the type of cells in the retina that are primarily affected ---cones or rods---, the age of onset of the first symptoms, and the progression of degeneration over the years[@b2]. Accordingly, the spectrum of IRD comprises diseases that predominantly affect (i) the central retina, such as Stargardt disease (STGD), cone dystrophy (CD), cone--rod dystrophy (CRD), and achromatopsia (ACHR); (ii) the peripheral retina, such as retinitis pigmentosa (RP); or (iii) both, such as Leber congenital amaurosis (LCA). However, some patients do not display specific clinical representations associated with a particular IRD, but exhibit overlapping phenotypes that are consistent with more than one particular dystrophy. Moreover, intrafamilial variability and incomplete penetrance are not uncommon, so assigning a definitive and precise clinical diagnosis can be difficult. In most cases, the retina is the only affected tissue (non-syndromic forms), while in some patients, other tissues can also be involved (syndromic forms)[@b3]. The latter includes Usher syndrome (US), Bardet-Biedl syndrome (BBS), and Joubert syndrome (JS), among others. In some families, discrimination between a non-syndromic or syndromic IRD is not always simple, as the existence of affected tissues other than the retina can be coincidental[@b4]. In this regard, genetic analysis becomes essential, as it is the only current tool that has the potential to provide a reliable and conclusive diagnosis. Nevertheless, providing a molecular diagnosis for these pathologies can be challenging due to the large number of candidate genes (\>200) and mutations (\>4,000) described, the absence of major genes or mutations, multiple inheritance patterns (autosomal dominant, autosomal recessive, and X-linked), the possible existence of modifier alleles, and the presence of non-causative variants[@b5].

Previously, conventional genetic diagnosis of IRD patients was based on the use of arrayed primer extension reactions (APEX) and Sanger sequencing method, which allow for the examination of known mutations or specific exons and gene targets[@b6]. However, these techniques guarantee the identification of the causative mutations in only 10--20% of cases[@b7]. More recently, next-generation sequencing (NGS) technologies have revolutionized genetic diagnosis of IRD. These methods facilitate the simultaneous screening of a large number of genes, are at least 1,000 times faster than conventional sequencing, and are much less expensive per sequence[@b8]. Within this context, some authors have opted to develop their own disease-specific gene panels that include a list of genes responsible for one particular IRD subtype[@b9][@b10][@b11][@b12][@b13][@b14], but they can only be applied when a clinical interpretation can be made with relative assurance[@b15].

Different studies suggest that 35% of IRD cases remain unsolved at the genetic level[@b2]; however, it is thought that the most common IRD genes have already been identified. Therefore, undiagnosed patients may carry mutations either in syndromic genes (usually not analyzed in non-syndromic patients), in genes associated with other IRD subtypes (not included in disease-specific panels), or in as-yet-unknown IRD genes[@b4][@b16]. This fact suggests that the best approach for the genetic diagnosis of these pathologies may be the simultaneous analysis of known genes responsible for both syndromic and non-syndromic forms of all IRD types. This could be through targeted/custom non-disease-specific panels or through more broad-based NGS strategies such as whole exome sequencing (WES) or whole genome sequencing (WGS). Within this context, new associations between already-known IRD genes and particular phenotypes would be established. Indeed, during the last few years, many IRD genes have been reclassified using these approaches[@b12][@b17][@b18][@b19][@b20][@b21]. In the present study, we used WES to examine 212 genes responsible for more than 25 syndromic and non-syndromic retinal dystrophies in a cohort of 59 unrelated families affected by a wide range of IRD phenotypes.

Results
=======

Clinical diagnosis of IRD patients
----------------------------------

Almost 89% of the cases included in our cohort had a well-defined clinical diagnosis (52/59). Most of the phenotypes were non-syndromic (53/59), with RP being the most common of the IRD (26 isolated cases and six US cases), followed by CD and STGD (six and five cases, respectively) ([Table 1](#t1){ref-type="table"}). In seven cases (11.86%), a specific clinical diagnosis could not be assigned, as the displayed phenotype was compatible with two, or even three, different retinal dystrophies (unclear phenotype).

WES approach for the genetic diagnosis of IRD patients
------------------------------------------------------

Ion Ampliseq^TM^ Exome technology and Ion Proton^TM^ platform allowed for the capturing, amplification and sequencing of more than 97% of the coding regions of \>19,000 genes. The generated data was filtered to obtain coverage information and variants of 212 genes included in our IRD panel (the full list of genes is given in [Supplementary Table S1](#S1){ref-type="supplementary-material"}). In particular, 5,294 amplicons covered 98.4% of the coding regions and flanking exon/intron boundaries (around 50 bp) of the IRD genes. After the analysis, 96.9% of target regions had a coverage of \>20x, 90% had \>40x, 56.4% had \>100x, and 12.8% had \>200x. Only 3% of the amplicons had coverage of \<20x ([Supplementary Fig. S1](#S1){ref-type="supplementary-material"}).

On average, depth coverage of IRD genes was 121x, with values that ranged from 52x (*CHM*) to 217x (*NRL*). Most of the genes (73.5%, 147/212) displayed an average depth of \>100x. A schematic representation of the percentage of nucleotides covered at different depth ranges, as well as the mean value for each gene, is shown in [Fig. 1](#f1){ref-type="fig"}.

For each sample, a mean of 1,050 variants were identified in the 212 genes, including single nucleotide variants and small indels. After discarding common polymorphisms (MAF \> 0.01), putative false-positives (depth \< 15x), and non-deleterious variants (synonymous substitutions, UTR variants), a mean of 14 variants remained, for which we used different prediction tools to evaluate their putative pathogenic impact. In addition, cosegregation studies were performed when relatives' samples were available. In the present study, a total of 63 different causative mutations were identified in 29 distinct genes ([Table 2](#t2){ref-type="table"}). *ABCA4, USH2A*, and *PDE6A* were the most frequent causative genes in our cohort (the frequency distribution of each gene is shown in [Fig. 2a](#f2){ref-type="fig"}). Of the 63 mutations, 21 were identified for the first time (33.3%). A deleterious function of new missense variants was attributed when at least three of the four prediction programs assigned a damaging or disease-causing effect (see [Supplementary Table S2](#S1){ref-type="supplementary-material"}). In family Fi15/09, the missense variant c.3G \> A affected the first methionine of *PROM1*; therefore, it was assumed to be deleterious, regardless of the bioinformatic predictions. The pathogenic effect of novel variants located in introns was estimated using five splice site predictors. Only those variants estimated to weak canonical splice sites, or those that create new donor or acceptor sites, were considered pathogenic ([Supplementary Table S3](#S1){ref-type="supplementary-material"}). The identified mutations were mainly missense (43%), followed by small deletions (24%), nonsense (17%), splicing (9%), small insertions (5%), and gross deletions (2%) ([Fig. 2b](#f2){ref-type="fig"}).

The causative mutation (or mutations) was identified in 71.18% of the families (42/59). The mutation detection rate varied considerably depending on the retinal dystrophy subtype. In some diseases, such US and LCA, it reached 100%; however, in CD and CRD, it did not exceed 35% ([Fig. 2c](#f2){ref-type="fig"}). Regarding RP, pathogenic mutations were identified in 18/26 cases (69.2%). Interestingly, phenotypic unclear cases reached a mutation detection rate of 71.4% (5/7). Finally, the genetic diagnosis was inconclusive in 17 families, representing 28.81% of the cohort, although in four of these, we identified one putative pathogenic variant in a recessive gene (see [Supplementary Table S4](#S1){ref-type="supplementary-material"}).

*CDHR1* as a candidate for retinitis pigmentosa with early macular affectation
------------------------------------------------------------------------------

Spanish family Fi15/19 contained three affected members from two different branches (two siblings, III:1 and III:2, and their cousin, III:4) who developed progressive nyctalopia and a reduction in peripheral visual field during the second decade of life ([Fig. 3a](#f3){ref-type="fig"}). Patient III:4 presented a best-corrected visual acuity (BCVA) of 20/32 and 20/40 at the ages of 25 and 35 years, respectively. BCVA decreased rapidly between the fourth and fifth decade of life, progressing to light perception at the age of 45. Fundus examination of the affected members of the family revealed typical signs of RP, including marked attenuation of the retinal blood vessels, waxy pallor of the optic discs, and pigmented bone spicules in the periphery ([Fig. 3b](#f3){ref-type="fig"}). Retinal autofluorescence showed diffuse RPE disturbances, both in the periphery and the macula. The macula showed a mottled hypoautofluorescence, similar to that seen in the very early stages of CRD, but without the characteristic RPE atrophy seen in the later stages ([Fig. 3c](#f3){ref-type="fig"}). Electroretinography (ERG) showed abolished responses in scotopic conditions. The a-wave was also undetectable in photopic ERG, though there was a clearly reduced, but detectable, b-wave ([Fig. 3d](#f3){ref-type="fig"}). The clinical and electrophysiological findings showed some overlapping traits between CRD and RP. However, the initial symptoms were clearly dominated by nyctalopia and peripheral visual field loss, while central vision decreased later, although to a much greater extent than found for most cases of RP. Altogether, these findings support a diagnosis of RP with early macular degeneration for this particular family.

Genetic analysis using the IRD panel showed that patient III:4 carried a frameshift mutation (c.1868_1869insA, p.Asn623Lysfs\*53) in compound heterozygosity with a splicing variant (c.1485 + 2T \> C) in the *CDHR1* gene. The first variant was considered to be new as it was not found in any public or private database, whereas the splicing variant was previously described in patients affected with a diffuse retinal dystrophy involving both cones and rods[@b22]. Cosegregation analysis of family Fi15/19 revealed that the variants came from different alleles, that no healthy sibling carried both variants, and that affected members III:1 and III:2 only carried the c.1868_1869insA variant. At this point, all coding regions of *CDHR1* were analyzed by Sanger sequencing in patient III:2, finding a previously unknown putative pathogenic splicing variant, c.1554-2A \> C ([Fig. 3a](#f3){ref-type="fig"}). All the splicing predictors defined this new variant as clearly pathogenic ([Supplementary Table S3](#S1){ref-type="supplementary-material"}).

In order to confirm the pathogenicity of these three *CDHR1* variants *in vivo*, RT-PCR analysis was performed on RNA blood samples from two affected members (III:1 and III:2), four carriers (III:3, III:6, III:8, and IV:1), and one non-related control individual (wild-type \[WT\]). The results revealed that affected patients and most carriers presented lower levels of the *CDHR1* canonical isoform compared with the WT (934 bp band in [Fig. 3e](#f3){ref-type="fig"}). Interestingly, family members III:1, III:2 and III:3 (carriers of the c.1554-2A \> C variant) also showed a 705 bp band that skipped exon 15 of the gene. This generated transcript created several premature termination codons (PTC) and apparently did not undergo nonsense-mediated mRNA decay (NMD), maybe due to the position of the first PTC, located in the second-to-last exon. On the other hand, members III:6, III:8 and IV:1 (carriers of the c.1485 + 2T \> C variant) produced a 769 bp band, which directly linked exons 12 and 14, and generated an in-frame transcript that likely translates to a CDHR1 protein that lacks 55 amino acids of two cadherin domains. Concerning the frameshift mutation (c.1868_1869insA), it was detected at the cDNA level of the carriers, suggesting that this variant also avoids NMD.

Novel functional studies of IRD mutations
-----------------------------------------

### Retinitis pigmentosa

Pedigree Fi15/20 is a Spanish consanguineous family with two siblings severely affected by RP. The analysis of the IRD panel in patient III:2 revealed a novel homozygous missense mutation in *MERTK*, c.1961G \> T (p.Gly654Val). This variant cosegregated with the disease ([Fig. 4a](#f4){ref-type="fig"}--i) and was predicted as deleterious by different missense prediction algorithms ([Supplementary Table S2](#S1){ref-type="supplementary-material"}). Interestingly, the variant affected the first nucleotide of exon 15 (a highly conserved guanine), which highlighted a putative effect on the splicing mechanism. In accordance with the splicing predictors, this variant abolishes the recognition of the intron 14 acceptor site ([Supplementary Table S3](#S1){ref-type="supplementary-material"}). To assess whether the c.1961G \> T mutation resulted in an altered splicing pattern, we performed a comparative RT-PCR analysis of *MERTK* in RNA from white blood cells of the affected siblings (III:2 and III:4), one carrier (IV:1), and one non-related control individual (WT), using primers located within exons 11 and 18 of the gene (see [Supplementary Table S5](#S1){ref-type="supplementary-material"} for primer sequences). The WT sample produced a single 857 bp band, as was expected from analysis of a correctly spliced transcript, whereas both patients and the carrier showed not only the WT band, but also another lower band of 738 bp, which lacked exon 15 and directly fused exons 14 and 16 ([Fig. 4a](#f4){ref-type="fig"}--ii). This aberrant transcript contained PTC and was found abundantly in the patients, indicating that it probably avoids the NMD degradation mechanism. The level of WT transcript was quantified in each sample using real-time RT-PCR, showing that the carrier individual produced around 38% WT transcript, whereas the patients only expressed 5--10%, compared with the control sample ([Fig. 4a](#f4){ref-type="fig"}--iii). However, it is worth mentioning that this small amount of correct mRNA still carried the missense mutation, which is predicted to be deleterious.

### Usher syndrome

The analysis of individual III:2, of the Spanish family Fi15/36, who was diagnosed with US, identified two novel mutations in *CDH23*: a deletion of a single nucleotide that creates a frameshift mutation (c.5546del, p.Pro1849Leufs\*4), and a splicing variant (c.7482 + 1G \> A) ([Fig. 4b](#f4){ref-type="fig"}--i). In order to assess the effects of the two variants on *CDH23* expression, RT-PCR analysis of blood samples from the patient and a non-related WT individual was performed using primers located in exons 39 and 54. In contrast with the WT sample, two different transcripts were obtained from the affected patient: one corresponding to the WT band (2,566 bp), and another (2,446 bp) skipping exon 51 ([Fig. 4b](#f4){ref-type="fig"}--ii). This finding suggests that the c.7482 + 1G \> A splicing variant weakens the canonical donor splice site of exon/intron 51. The direct link between exons 50 and 52 generated an in-frame transcript that likely produces a CDH23 protein that lacks 40 amino acids of a highly conserved sequence of the extracellular domain. Concerning the c.5546del frameshift mutation, Sanger sequencing of the obtained WT band from the patient's cDNA suggested that the aberrant transcript did not undergo NMD degradation, as the chromatogram showed double peaks starting from the variant position ([Fig. 4b](#f4){ref-type="fig"}--iii).

### Leber congenital amaurosis

Family Fi15/12, which contained one male affected with LCA, was previously genetically analyzed by de Castro-Miro *et al*. using a cosegregation chip based on SNP genotyping, followed by Sanger sequencing of the candidate genes[@b23]. This analysis identified two new variants in *RPGRIP1*, a deletion of two nucleotides that created a frameshift mutation (c.895_896del, p. Glu299Serfs\*21), and an intronic variant with unknown pathogenic effect (c.2367 + 23del) ([Fig. 4c](#f4){ref-type="fig"}--i). However, the genetic diagnosis was finally inconclusive, as the pathogenic impact of the intronic variant could not be proved. At this point, with consideration of the family's interest in obtaining a reliable molecular diagnosis, the affected patient was analyzed using the IRD panel. Nevertheless, no clearly pathogenic mutations were detected other than the two *RPGRIP1* variants. Within this context, we aimed to evaluate the pathogenic impact of the c.2367 + 23del variant, which did not show any substantial pathogenic impact according to the *in silico* predictions (see [Supplementary Table S3](#S1){ref-type="supplementary-material"}). The *RPGRIP1* gene displays high transcriptional complexity, with two different promoters (the canonical one and another internal promoter located before exon 10) and several alternative exons. Previous studies in animal models have revealed that many of the *RPGRIP1* isoforms are likely to have tissue-specific expression, and that both promoters are active in the retina, whereas only the one with the transcription start site in exon 10 is active in other tissues such as the lung, heart, or testis[@b24][@b25]. Thus, we first assessed the expression of *RPGRIP1* isoforms in human blood by using several pairs of primers, with cDNA amplification obtained when using primers located after exon 10, suggesting that the internal promoter is the only one active in this tissue. Taking into account these results, RT-PCR analysis using primers located at exons 14 and 17 was performed in the affected patient (III:2), his carrier parents (II:3 and II:4), the carrier brother (III:1) and the noncarrier sister (III:3). (see [Supplementary Table S5](#S1){ref-type="supplementary-material"} for primer sequences). All family members expressed two different bands, the WT band (665 bp) and a lower one (170 bp) that lacked exons 15 and 16 ([Fig. 4c](#f4){ref-type="fig"}--ii). Intrafamilial variable expression of these two transcripts was observed. At this point, we aimed to quantify by real-time RT-PCR the amount of WT transcript in each case, using a Taqman probe located between exons 14 and 15 ([Fig. 4c](#f4){ref-type="fig"}--iii). Interestingly, those family members who carried the intronic variant exhibited reduced expression of the WT isoform ranging from 37--75%. This suggests that the c.2367 + 23del variant strongly impairs the recognition of *RPGRIP1* canonical splice sites, favoring the production of the transcript that skips exons 15 and 16. The latter would likely generate an in-frame sequence that lacks 492 nucleotides (164 amino acids) that code for the C2 protein domain, which is responsible for RPGRIP1 interaction with other proteins in the ciliary transition zone. In this regard, several *RPGRIP1* deleterious mutations have been shown to disrupt this interaction[@b26][@b27].

Discussion
==========

Some authors claim that custom targeted-NGS of specific panels is the best strategy for genetic screening of IRD, and that WES is useful for uncovering new candidate genes involved in these diseases only when known genes have already been ruled out[@b28]. In this report, we propose that WES is an effective tool not only for the identification of new genes, but also for routine IRD molecular diagnosis. Within this context, we used Ion Proton^TM^ system to sequence coding regions of \> 19,000 genes and specifically analyze a panel of 212 IRD candidates in a cohort of 59 genetically and clinically unselected families. The pathogenic variants were detected in 71.18% of cases (42/59), reaching a mutation detection rate higher than most previous studies, where either custom targeted-NGS or WES was used ([Table 3](#t3){ref-type="table"})[@b9][@b10][@b11][@b13][@b19][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39]. The improvement displayed in our study may be explained by a number of different factors: i) more accurate clinical characterization, which assures that all patients included in the cohort show features compatible with retinal dystrophies caused by a genetic alteration; ii) superior gene panel design, ensuring inclusion of all potential candidates; iii) a more optimal data analysis pipeline (for example, 15x as the acceptable coverage threshold); and iv) better coverage of the genes of interest, especially those that contain mutational hotspots or prevalent variants.

WES offers several advantages compared to targeted-NGS, especially in genetic heterogeneous diseases such as IRD, for which novel disease genes are continually being discovered. In this regard, targeted-NGS is limited in its flexibility for including new disease candidates, whereas the WES strategy allows for rapid enlargement of the panel. Moreover, for unsolved cases, once all known genes have been ruled out by WES, the same generated data can be used for the identification of new candidates located throughout the entire exome. However, it is worth mentioning that targeted-NGS retains some advantages as it can achieve a higher depth of coverage in the regions of interest than that possible with WES[@b37]. In our case, the mean depth of the genes included in the panel was 121x, whereas in most targeted-NGS studies, this value ranged between 250x and 1,330x ([Table 3](#t3){ref-type="table"})[@b9][@b10][@b13][@b19][@b31][@b36][@b37]. A greater depth of coverage not only reduces the detection of false-positives, but also allows for the analysis of copy number variations (CNV)[@b4][@b6]. However, in complex sequences such as exon ORF15 of *RPGR*, custom targeted-NGS does not achieve better coverage than that possible with WES. Our strategy allowed for the analysis of 76% of the whole *RPGR* gene and 41% of exon ORF15, with these values being similar to previous target-NGS studies[@b9]. Within this context, we were able to identify by WES a frameshift mutation in exon ORF15 in one patient of the cohort (Fi15/41).

In our study, CNV detection was not possible due to the average depth obtained; thus, we assume that gross rearrangements may be responsible for a proportion of the genetically undiagnosed patients (28.82%). Additionally, the failure to identify mutations in these patients may be due to the causative variants being located in coding regions poorly covered by WES, in non-coding regions or regulatory sequences, or in novel genes that have not yet been associated with IRD. Interestingly, the percentage of unsolved patients was significantly higher in CD and CRD in comparison to other conditions (see [Fig. 2c](#f2){ref-type="fig"}), suggesting that these dystrophies have been studied to a lesser extent, and that more novel genes are yet to be discovered for these particular phenotypes.

The phenotypic overlap of retinal dystrophies greatly diminishes the ability to arrive at an accurate clinical diagnosis. In fact, some authors estimate that IRD patients visit an average of seven ophthalmologists before the final diagnosis is made[@b40]. In our cohort, a significant group of patients (11.86%) showed clinical features that were compatible with different retinal dystrophies, prompting us to design a non-disease-specific panel that encompassed all syndromic and non-syndromic IRD genes. Once the analysis was performed, the pathogenic mutation was successfully identified in almost 72% of the families with an unclear phenotype, providing evidence that our strategy is effective not only for patients with a precise and particular clinical diagnosis, but also for cases with uncertain phenotypic features. Moreover, this non-hypothesis-driven approach allowed us to propose the already known IRD gene *CDHR1* as a good RP candidate. This gene was previously described in families mainly affected by CRD[@b41][@b42][@b43], or by a retinal dystrophy that involves both rods and cones at the same time[@b22][@b44]. In our study, family Fi15/19 was found to carry mutations in *CDHR1*, and displayed the main clinical traits corresponding to autosomal recessive RP, with a remarkable premature degeneration of cones. These particular traits are similar to those observed in some patients that carry mutations in *PROM1*, a gene also involved in RP and CRD[@b45]. In fact, PROM1 and CDHR1 proteins co-localize at the base of the developing outer segment of photoreceptors, with both participating in disc morphogenesis[@b46]. This suggests that their alterations could lead to similar clinical phenotypes. Here, we propose *CDHR1* as a good candidate in molecular genetic studies of patients showing either CRD or RP symptoms, and add two new mutations to the molecular spectrum of this gene. Previously, only seven different *CDHR1* variants have been described, most of them resulting in premature stop codons or splicing alterations that should lead to NMD. In this work, we report for the first time *in vivo* functional assays for *CDHR1* mutations that demonstrate that pathogenic mechanisms other than NMD may be responsible for the deleterious effect of truncating/splicing variants.

In addition to basic molecular genotyping, in certain cases, functional studies are needed in order to provide a conclusive genetic diagnosis. This was the case for family Fi15/12, who carry an intronic deletion in *RPGRIP1* (c.2367 + 23del) that, according to *in silico* prediction programs, has a slight effect on splicing. However, here we provide *in vivo* functional evidence that this variant has a clear impact on the *RPGRIP1* splicing mechanisms. Similarly, a recent study demonstrated the pathogenic effect of a prevalent *ABCA4* intronic mutation, c.5461-10T \> C, which was also predicted to be neutral by bioinformatic tools[@b47]. Together, these studies highlight the importance of functional analysis, with splicing predictors being frequently difficult to interpret and sometimes unreliable, especially for variants located outside of the intronic canonical signals. In addition, *in vivo* studies of mutations present in heterogeneous diseases, such as those investigated in the present analysis, are also useful for the establishment of genotype--phenotype correlations. This is the case for *CDH23*, where previous work has shown that truncated peptides or loss of numerous amino acid residues in the CDH23 protein results in US, whereas missense mutations cause non-syndromic deafness[@b48][@b49]. Such evidence is in accordance with the *in vivo* results that we obtained from the analysis of family Fi15/36, who is affected by US, and carries two new mutations altering the open reading frame of *CDH23*.

In conclusion, we analyzed a large cohort of clinically heterogeneous IRD patients using WES, and report a diagnostic yield greater than 70%. Altogether, our results indicate that WES using Ion Proton^TM^ system is a valuable strategy for application to IRD.

Methods
=======

Patients
--------

A cohort of 59 clinically and genetically unselected IRD families was included in the present study. None of the families was previously screened for gene mutations, except pedigree Fi15/12 that presented previous genetic data[@b23], which was inconclusive and therefore not considered in this work. Most patients originated from Spain (n = 46), while the others were from the Arabian Peninsula (n = 11), Venezuela (n = 1), and Costa Rica (n = 1). Clinical diagnoses were established at the Institut de Microcirurgia Ocular (Barcelona, Spain) and were based on standard ophthalmic evaluations (best corrected visual acuity, retinography, fundus autofluorescence, optical coherence tomography, electroretinography, and visual field). Peripheral blood (in EDTA tubes) or saliva samples were obtained from patients and their relatives. Automated extraction of genomic DNA was performed by using the KingFisher Duo purification system (Thermo Fisher Scientific, Waltham, MA). All procedures used in this study were in accordance with the Declaration of Helsinki. Ethics approval was received from the Ethics Committee of Institut de Microcirurgia Ocular (160321_96). All patients and their relatives were fully informed of the purpose and procedures of this study, and written consent was obtained from each individual.

Gene panel design, whole exome sequencing and data processing
-------------------------------------------------------------

A total of 212 genes previously associated with inherited retinal disorders were included in our IRD panel. Genes were selected according to the information available in RetNet (<https://sph.uth.edu/retnet/>) and Pubmed databases (<http://www.ncbi.nlm.nih.gov/pubmed/>). These genes were known to be responsible for 13 non-syndromic IRD forms (CD, CRD, LCA, RP, ACHR, STGD, congenital stationary night blindness, gyrate atrophy, familial exudative vitreoretinopathy, choroideremia, Sorsby's dystrophy, Norrie disease, and retinoschisis) and more than 10 syndromic diseases (US, BBS, JS, Alström syndrome, Senior--Løken syndrome, Stickler syndrome, Alport syndrome, Alagille syndrome, Wagner disease, and oculoauricular syndrome, among others).

WES was performed in patients from 59 unrelated families using libraries designed and constructed using the Ion AmpliSeq^TM^ Exome technology (ThermoFisher Scientific). Generated amplicons were genotyped with the Ion Proton^TM^ platform (Life Technologies), following the manufacturer's instructions. Sequences were aligned against the reference genome (GRCh37/hg19) by using TMAP Alignment (Thermo Fisher Scientific). WES was performed in collaboration with a private company (NIMGenetics, Madrid, Spain), which provided the BAM, BAI, and FASTQ files, as well as VCF and TSV files that contained a compilation of all of the variants detected using the Ion Reporter software (Thermo Fisher Scientific). Moreover, the company supplied a TSV file that specifically included the variants identified in the 212 genes (after running a custom pipeline), and a document that detailed the coverage data of the panel, specifying the number of reads of each amplicon. The coverage information obtained from the 59 samples was used to measure the average depth and coverage percentage of each gene.

Determination of pathogenic variants
------------------------------------

Variants that were detected in genes included in the IRD panel were filtered according to coverage (≥15x), minor allele frequency (≤0.01), and deleterious potential. All resulting variants were contrasted with the mutation databases, HGMD (<http://www.hgmd.cf.ac.uk/ac/index.php>) and Uniprot (<http://www.uniprot.org/>). The pathogenicity of missense changes was evaluated using the following *in silico* predictors: SIFT, MutationTaster, PolyPhen-2, and Align GV-GD. When new variants potentially affected the splicing mechanism, the splice site score values of the wild-type and the mutated sequence were predicted online using SpliceSite, MaxEntScan, NNSPLICE, GeneSplicer and Human Splicing Finder. Moreover, nucleotide conservation was evaluated using the PhastCons and PhyloP programs.

Sanger sequencing was performed to confirm all of the putative pathogenic variants obtained after WES genotyping, and mutation segregation analysis was carried out when relatives' samples were available.

In partially solved recessive cases, with only one pathogenic variant detected in an IRD gene, the coverage data of this gene was carefully evaluated, and those regions poorly covered (\<15x) were Sanger sequenced. If the second pathogenic allele was not found, and gross deletion or duplication rearrangements were previously described in the gene of interest, a copy number variation analysis was also carried out. In particular, in family Fi15/40, a deletion/duplication analysis for *GPR98* was performed using a custom designed gene centric microarray (Baylor Miraca, Houston, TX). In family Fi15/44 [Supplementary Table S4](#S1){ref-type="supplementary-material"}, multiplex ligation-dependent probe amplification (MLPA) analysis was used to evaluate the presence of rearrangements of *USH2A* (SALSA MLPA probemixes P361 and P362).

RNA expression
--------------

Total RNA from particular patients and their relatives was obtained from 500 μl of blood stabilized with 1.3 ml of RNAlater by using the RiboPure-Blood purification kit (Thermo Fisher Scientific), according to the manufacturer's instructions. First, cDNA chains were obtained by reverse transcription (RT) using the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics, Indianapolis, IN). Specific amplification of transcripts was obtained for *MERTK, RPGRIP1, CDH23* or *CDHR1* genes. *GAPDH* was used as a control for normalization. Primer sequences are given in [Supplementary Table S5](#S1){ref-type="supplementary-material"}.

Quantitative real-time RT-PCR was performed using Taqman^TM^ Gene Expression Assays (Applied Biosystems, Carlsbad, CA) from 20--30 ng of cDNA per well. Relative gene expression was assayed in triplicate and compared with wild-type samples, which served as the set point. All real-time RT-PCR reactions were performed on a QuantStudio 3 instrument (Applied Biosystems), following the manufacturer's instructions. Housekeeping genes β*2 M, GAPDH* and *ACTB* were used for normalization. Relative quantification was assessed by using the 2^−ΔΔCT^ method. Taqman Gene Expression Assays references were Hs00187842_m1 (β*2 M*), Hs99999905_m1 (*GAPDH*), Hs01060665_g1 (*ACTB*), Hs01031970_m1 (*MERTK*) and Hs00971456_g1 (*RPGRIP1*).
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![Coverage statistics of coding regions of genes included in the panel.\
The percentage of nucleotides with 0x, 1x--14x, 15x--34x, or ≥35x depth coverage per gene is shown. Black lines represent the average depth in each case.](srep42078-f1){#f1}

![Mutations identified in a cohort of 59 IRD families using a targeted WES strategy.\
(**a**) Distribution and frequencies of IRD genes. *ABCA4, USH2A* and *PDE6A* were the most prevalent genes. (**b**) Types of mutations identified and their frequencies. (**c**) Comparison of the mutation detection rate of different IRD subtypes. Abbreviations: ACHR, achromatopsia; CD, cone dystrophy; CRD, cone--rod dystrophy; GA, gyrate atrophy; LCA, Leber congenital amaurosis; RP, retinitis pigmentosa; STGD, Stargardt disease; US, Usher syndrome.](srep42078-f2){#f2}

![Identification of *CDHR1* mutations in a family affected by RP.\
(**a**) Cosegregation analysis of *CDHR1* variants identified in family Fi15/19. (**b** and **c**) Fundus eye photographs and autofluorescence images of the affected member III:2. (**d**) Electroretinographic recordings under scotopic (0 dB) and photopic (0 dB) conditions from both eyes of patient III:4. A b-wave could be detected in photopic ERG (amplitude and latency values are shown). Photopic 30-Hz flicker (0 dB) was also recorded. (**e**) RT-PCR analysis of *CDHR1* blood mRNA of affected patients (III:1 and III:2), carriers (III:3, III:6, III:8, and IV:1), and one control individual (WT). Patients and carriers showed a dramatic decrease in the *CDHR1* normal transcript. III:1, III:2, and III:3, who carry c.1554-2A \> C, also produced a lower mass band corresponding to an mRNA that skips exon 15, whereas members III:6, III:8 and IV:1, carriers of c.1485 + 2T \> C, presented a 769 bp band that directly links exon 12 and 14 of the gene.](srep42078-f3){#f3}

![*In vivo* functional studies of variants identified in *MERTK, CDH23*, and *RPGRIP1* genes.\
(**a-i**) Pedigree of consanguineous family Fi15/20, showing the cosegregation analysis of variant c.1961G \> T of *MERTK*. (**a-ii**) Electrophoresis gel of the RT-PCR products obtained from affected patients (III:2 and III:4), carrier (IV:1), and WT blood samples. Patients produced high levels of an aberrantly spliced transcript, whereas the WT produced only the expected 857 bp band. (**a-iii**) Quantitative analysis of *MERTK* levels by real-time RT-PCR. The WT sample was set at 100%. (**b-i**) Cosegregation analysis of the two new *CDH23* variants identified in family Fi15/36. (**b-ii**) RT-PCR assay using blood samples from the affected patient (III:2) and an unrelated WT individual. Two different bands were obtained in the patient, the expected one and another skipping exon 51. (**b-iii**) Chromatogram of the 2,566 bp band obtained from cDNA of patient III:2. (**c-i**) Fi15/12 family pedigree and *RPGRIP1* variants cosegregation. (**c-ii**) RT-PCR analysis revealed intrafamilial differences in the expression of *RPGRIP1* gene. (**c-iii**) Quantification of *RPGRIP1* canonical transcript by real-time RT-PCR. The noncarrier family member III:3 was used as a control, and her sample was set at 100%.](srep42078-f4){#f4}

###### Clinical classification of the families included in our cohort.

  Disease                       Families   Percentage
  ---------------------------- ---------- ------------
  Retinitis pigmentosa             26        44.06%
  Usher syndrome                   6         10.16%
  Cone dystrophy                   6         10.16%
  Stargardt disease                5         8.47%
  Leber congenital amaurosis       4         6.77%
  Cone-rod dystrophy               3         5.08%
  Achromatopsia                    1         1.69%
  Gyrate atrophy                   1         1.69%
  Unclear phenotype                7         11.86%
  Total                            59         100%

###### Overview of the variants obtained in the genetically solved cases of our cohort.

  Family ID                                                   Phenotype       Gene                    Allele 1                                   Reference                           Allele 2               Reference                       Segregation                              
  ------------------------------------------------------- ----------------- --------- ----------------------------------------- -------------------------------------------- ------------------------ --------------------- ------------------------------------------- ------------ -----
  **Autosomal dominant cases** (**6/42**, **14.28%**)                                                                                                                                                                                                                                
  Fi15/01[\*](#t2-fn1){ref-type="fn"}                            CD          GUCY2D                 c.2513G \> A                                 Arg838His                            [@b50]                                                                                          Yes
  Fi15/02[\*](#t2-fn1){ref-type="fn"}                            CD          GUCY2D                 c.2512C \> T                                 Arg838Cys                            [@b51]                                                                                          Yes
  Fi15/03[\*](#t2-fn1){ref-type="fn"}                         MD vs SFD       TIMP3                  c.499G \> A                                 Asp167Asn                          This study                                                                                        Yes
  Fi15/04[\*](#t2-fn1){ref-type="fn"}                            LCA           CRX                    c.785del                   Ser262Thrfs[\*](#t2-fn1){ref-type="fn"}109         This study                                                                                        Yes
  Fi15/05[\*](#t2-fn1){ref-type="fn"}                            RP           PRPF8                 c.6926A \> G                                 His2309Arg                           [@b52]                                                                                          Yes
  Fi15/06[\*](#t2-fn1){ref-type="fn"}                            RP            RHO                   c.872C \> G                                 Pro291Arg                          This study                                                                                        No
  **Autosomal recessive cases** (**34/42**, **80.95%**)                                                                                                                                                                                                                              
  Fi15/07                                                       ACHR          CNGA3                  c.847C \> T                                 Arg283Trp                            [@b53]               c.847C \> T                       Arg283Trp                     [@b53]     No
  Fi15/08                                                    ACHR vs CD       PDE6C                 c.1574G \> T                                 Gly525Val                          This study            c.1574G \> T                       Gly525Val                   This study   Yes
  Fi15/09                                                        CRD          PROM1                   c.3G \> A                                   Met1Ile                           This study           c.1354_1355insT     Tyr452Leufs[\*](#t2-fn1){ref-type="fn"}13     [@b54]     Yes
  Fi15/10                                                        GA            OAT                   c.627T \> A                                 Tyr209Ter                            [@b55]               c.627T \> A                       Tyr209Ter                     [@b55]     Yes
  Fi15/11                                                        LCA         CEP290                c.1864_1865del                 Asp622Phefs[\*](#t2-fn1){ref-type="fn"}5          This study            c.4723A \> T                      Lys1575Ter                     [@b56]     Yes
  Fi15/12                                                        LCA         RPGRIP1                c.895_896del                 Glu299Serfs[\*](#t2-fn1){ref-type="fn"}21            [@b23]             c.2367 + 23del                      Splicing                      [@b23]     Yes
  Fi15/13                                                        LCA          CRB1                  c.611_617del                 Ile205Aspfs[\*](#t2-fn1){ref-type="fn"}13            [@b57]              c.2843G \> A                       Cys948Tyr                     [@b58]     Yes
  Fi15/14                                                  LCA vs CD vs RP    CNGB3                   c.1148del                                   Thr383fs                            [@b59]                c.1148del                        Thr383fs                      [@b59]     Yes
  Fi15/15                                                        RP           PDE6A                 c.1630C \> T                                 Arg544Trp                            [@b60]              c.1630C \> T                       Arg544Trp                     [@b60]     Yes
  Fi15/16                                                        RP            EYS                  c.4120C \> T                                 Arg1374Ter                           [@b61]             c.4829_4832del      Ser1610Phefs[\*](#t2-fn1){ref-type="fn"}7   This study   Yes
  Fi15/17                                                        RP           PDE6A                 c.1630C \> T                                 Arg544Trp                            [@b60]              c.1630C \> T                       Arg544Trp                     [@b60]     Yes
  Fi15/18                                                        RP           USH2A                 c.2633G \> A                                 Arg878His                            [@b62]              c.11927C \> T                     Thr3976Met                     [@b63]     Yes
  Fi15/19[\*](#t2-fn1){ref-type="fn"}                            RP           CDHR1        c.1485 + 2T \> C/c.1554-2A \> C                        Splicing                        22/This study          c.1868_1869insA     Asn623Lysfs[\*](#t2-fn1){ref-type="fn"}53   This study   Yes
  Fi15/20[\*](#t2-fn1){ref-type="fn"}                            RP           MERTK                 c.1961G \> T                                 Gly654Val                          This study            c.1961G \> T                       Gly654Val                   This study   Yes
  Fi15/21[\*](#t2-fn1){ref-type="fn"}                            RP           USH2A                 c.12574C \> T                                Arg4192Cys                           [@b64]              c.12574C \> T                     Arg4192Cys                     [@b64]     Yes
  Fi15/22                                                        RP           PDE6B                  c.299G \> A                                 Arg100His                            [@b38]               c.299G \> A                       Arg100His                     [@b38]     Yes
  Fi15/23[\*](#t2-fn1){ref-type="fn"}                            RP           ABCA4                 c.1804C \> T                                 Arg602Trp                            [@b65]              c.5819T \> C                      Leu1940Pro                     [@b66]     Yes
  Fi15/24[\*](#t2-fn1){ref-type="fn"}                            RP           PRCD                   c.70C \> T                                   Gln24Ter                          This study             c.70C \> T                        Gln24Ter                    This study   Yes
  Fi15/25                                                        RP           RPE65                 c.292_311del                  Ile98Hisfs[\*](#t2-fn1){ref-type="fn"}26            [@b67]               c.419G \> A                       Gly140Glu                   This study   Yes
  Fi15/26[\*](#t2-fn1){ref-type="fn"}                            RP           PDE6B                   c.1860del                  His620Glnfs[\*](#t2-fn1){ref-type="fn"}23            [@b68]                c.1860del        His620Glnfs[\*](#t2-fn1){ref-type="fn"}23     [@b68]     No
  Fi15/27                                                        RP            EYS                  c.6111C \> A                                 Cys2037Ter                         This study            c.6111C \> A                      Cys2037Ter                   This study   No
  Fi15/28                                                        RP           PDE6A                  c.305G \> A                                 Arg102His                            [@b69]                c.1268del                        Leu423Ter                   This study   Yes
  Fi15/29[\*](#t2-fn1){ref-type="fn"}                         RP vs CRD       CRB1                  c.498_506del                              Ile167_Gly169del                        [@b70]              c.2843G \> A                       Cys948Tyr                     [@b58]     Yes
  Fi15/30                                                    ARB vs STGD      BEST1                   c.798del                   Gln327Argfs[\*](#t2-fn1){ref-type="fn"}42          This study              c.798del         Gln327Argfs[\*](#t2-fn1){ref-type="fn"}42   This study   Yes
  Fi15/31[\*](#t2-fn1){ref-type="fn"}                           STGD          ABCA4                c.5461-1G \> T                                 Splicing                          This study            c.6118C \> T                      Arg2040Ter                     [@b71]     Yes
  Fi15/32                                                       STGD          ABCA4    c.514G \> A, c.2023G \> A, c.6148G \> C        Gly172Ser, Val675Ile, Val2050Leu        [@b72], [@b73], [@b74]    c.3211_3212insGT      Ser1071fs[\*](#t2-fn1){ref-type="fn"}14      [@b74]     Yes
  Fi15/33[\*](#t2-fn1){ref-type="fn"}                           STGD          ABCA4                 c.3988G \> T                                 Glu1330Ter                           [@b64]              c.5882G \> A                      Gly1961Glu                     [@b74]     Yes
  Fi15/34                                                       STGD          ABCA4                 c.2041C \> T                                 Arg681Ter                            [@b75]              c.4919G \> A                      Arg1640Gln                     [@b76]     Yes
  Fi15/35[\*](#t2-fn1){ref-type="fn"}                            US           MYO7A                 c.3719G \> A                                 Arg1240Gln                           [@b77]             c.5886_5888del                     Phe1963del                     [@b78]     Yes
  Fi15/36                                                        US           CDH23                   c.5546del                  Pro1849Leufs[\*](#t2-fn1){ref-type="fn"}4          This study          c.7482 + 1G \> A                     Splicing                    This study   Yes
  Fi15/37                                                        US           USH2A                 c.10636G \> A                                Gly3546Arg                           [@b79]              c.10636G \> A                     Gly3546Arg                     [@b79]     Yes
  Fi15/38                                                        US           USH2A                 c.9799T \> C                                 Cys3267Arg                           [@b80]              c.9799T \> C                      Cys3267Arg                     [@b80]     Yes
  Fi15/39[\*](#t2-fn1){ref-type="fn"}                            US           CLRN1                 c.254-1G \> A                                 Splicing                          This study            c.254-1G \> A                      Splicing                    This study   Yes
  Fi15/40                                                        US           GPR98                c.7988_7989del                                Ser2663Ter                         This study         exon 2--50 deletion                Gross deletion                 This study   Yes
  **X-linked cases** (**2/42**, **4.76%**)                                                                                                                                                                                                                                           
  Fi15/41[\*](#t2-fn1){ref-type="fn"}                            RP           RPGR                 c.2235_2236del                Glu746Argfs[\*](#t2-fn1){ref-type="fn"}23            [@b81]                                                                                          Yes
  Fi15/42                                                        RP            RP2                   c.358C \> T                                 Arg120Ter                            [@b82]                                                                                          Yes

Asterisks (^\*^) highlight those families with more than one affected member, commas (,) separate variants in the same allele, and slashes (/) depict cases where different mutations were identified in different affected members of the same family. The number of genetically diagnosed families is shown for each inheritance, and the percentage of each pattern is calculated on the solved cases (42 in total). Abbreviations: ACHR, achromatopsia; ARB, autosomal recessive bestrophinopathy; CD, cone dystrophy; CRD, cone--rod dystrophy; GA, gyrate atrophy; LCA, Leber congenital amaurosis; MD, macular dystrophy; RP, retinitis pigmentosa; SFD, Sorsby's fundus dystrophy; STGD, Stargardt disease; US, Usher syndrome.

###### Comparison of mutation detection rate and coverage data of different studies that have been used next-generation sequencing for the genetic analysis of an IRD cohort.

  Reference                                  Mutation detection rate   Num. of patients   Patient's phenotype     Genes included                                    Method                                            Sequencing platform             Mean depth   \% bp \> 10X   \% bp \> 20X
  ----------------------------------------- ------------------------- ------------------ --------------------- --------------------- --------------------------------------------------------------------- ----------------------------------------- ------------ -------------- --------------
  **Whole exome sequencing**                                                                                                                                                                                                                                                     
  This study                                          71.1%                   59                  IRD              212 IRD genes                  Ion AmpliSeq^TM^ Exome (Life Technologies)                              Ion Proton                     121×         97.5%          96.9%
  Tiwari *et al*.[@b83]                                64%                    58                  IRD              250 IRD genes      SeqCap EZ NimbleGen (Roche)/ Nextera Rapid Capture Exome (Illumina)   Illumina HiSeq 2000/Illumina NextSeq500      ---           ---            ---
  Xin *et al*.[@b29]                                  57.6%                   33                 STGD              163 IRD genes                     SureSelect v4 (Agilent Technologies)                             Illumina HiSeq 2000                125×          ---            ---
  Beryozkin *et al*.[@b30]                            48.5%                   68                  IRD              226 IRD genes                          SeqCap EZ NimbleGen (Roche)                                 Illumina HiSeq 2000                80×           ---            ---
  **Targeted next-generation sequencing**                                                                                                                                                                                                                                        
  Bravo-Gil *et al*.[@b31]                             73%                    32                  IRD              64 IRD genes                    Custom SureSelect (Agilent Technologies)                             Illumina MiSeq                   409×          ---            ---
  Eisenberg *et al*.[@b11]                             70%                   126              RP and LCA        55 RP and LCA genes                       SeqCap EZ NimbleGen (Roche)                            Roche GS FLX/ Illumina MiSeq          75× 250×    90.0% 99.0%        ---
  Aparisi *et al*.[@b10]                              68.7%                   44                  US                14 US genes                         HaloPlex (Agilent Technologies)                                 Illumina MiSeq                  1334×          ---            ---
  Patel *et al*.[@b32]                                62.3%                  292                  IRD              322 IRD genes                 Ion Ampliseq custom panel (Life Technologies)                            Ion Proton                     ---           ---            ---
  Boulanger-Scemama *et al*.[@b19]                    62.1%                   95              CD and CRD           123 IRD genes                   Custom SureSelect (Agilent Technologies)                        Illumina Genome Analyzer              244×          ---            ---
  Zhao *et al*.[@b33]                                  60%                    82                  RP               186 IRD genes                 Ion Ampliseq custom panel (Life Technologies)                        Illumina HiSeq 2000                ---          95.1%           ---
  Perez-Carro *et al*. (2015)[@b9]                    57.4%                   47                  RP                75 RP genes                         HaloPlex (Agilent Technologies)                                 Illumina MiSeq                   722×         99.1%           ---
  Huang *et al*.[@b34]                                55.3%                  179                  IRD              164 IRD genes                             GenCap (MyGenostics)                                     Illumina HiSeq 2000                191×         98.2%           ---
  Glöckle *et al*.[@b13]                             55--80%                 170                  IRD              105 IRD genes                   Custom SureSelect (Agilent Technologies)                                  SOLiD                       750×          ---            ---
  O'Sullivan *et al*.[@b35]                          50--55%                  50                  RP               105 IRD genes                   Custom SureSelect (Agilent Technologies)                                  SOLiD                     **---**       **---**         92.0%
  Weisschuh *et al*.[@b36]                             50%                    50                  IRD              105 IRD genes                   Custom SureSelect (Agilent Technologies)                                  SOLiD                       750×        **---**        **---**
  Oishi *et al*.[@b37]                              36.3--50%                329               RP and US           193 IRD genes                        HaloPlex (Agilent Technologies)                               Illumina HiSeq 2500                250×         92.2%          88.7%
  Neveling *et al*.[@b38]                              36%                   100                  RP               111 IRD genes                           12-plex NimbleGen (Roche)                                     Roche GS FLX                    ---          89.0%           ---
  Shanks *et al*.[@b39]                                25%                    36                  IRD              73 IRD genes                            12-plex NimbleGen (Roche)                                       Roche 454                     ---          95.0%          85.0%

Studies are classified according to the method and sorted by descending order of mutation detection rate. Only those studies that included a minimum of 30 patients are mentioned. Abbreviations: CD, cone dystrophy; CRD, cone-rod dystrophy; IRD, inherited retinal dystrophies; LCA, Leber congenital amaurosis; RP, retinitis pigmentosa; STGD, Stargardt disease; US, Usher syndrome.
